CorMedix reports Q2 2026 results, flags REZZAYO filing and DefenCath supply deal
CorMedix expects to submit an sNDA for expanded REZZAYO use in Q3 2026 and signed a new dialysis supply agreement, while maintaining full-year revenue guidance.
CorMedix Inc. reported financial results for the quarter ended June 30, 2026, on August 13, 2026, along with a business update.
The company said that working with development partner Mundipharma, it expects to submit a supplemental New Drug Application in the third quarter of 2026 seeking an expanded indication for REZZAYO to prevent invasive fungal disease.1 If regulators accept the filing, CorMedix said it expects an FDA decision on the application in the first half of 2027.1
On the commercial side, CorMedix signed a new multi-year supply agreement for DefenCath with a large dialysis operator, extending its commercial reach to all five of the top U.S. dialysis service providers.1 That operator has begun ordering DefenCath and plans to start a pilot program in the third quarter of 2026.1
For the quarter, CorMedix reported $101.9 million in total revenue and grant income, which it called consolidated revenue.1 DefenCath contributed $66.1 million in net revenue, while the Melinta portfolio added $35.8 million.1 Net income was $26.0 million and adjusted EBITDA was $58.7 million.1
The company maintained its full-year 2026 consolidated revenue guidance of $325 to $345 million and raised its adjusted EBITDA guidance to a range of $125 to $140 million.1 Cash operating expense guidance was narrowed to $145 to $155 million.1
Cash and short-term investments, excluding restricted cash, totaled $256.7 million at June 30, 2026.1 CorMedix said it believes it has enough resources to fund operations for at least the next twelve months following the filing of its upcoming quarterly report.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.